- Policy
- Yoon’s transition team prepares for digital platform govnt
- by Lee, Jeong-Hwan Mar 25, 2022 05:48am
- President-elect Suk-Yeol Yoon’s presidential transition committee announced a policy with the state-led public prescription system in mind. In the process of announcing the creation of a task force (TF) to bring the digital platform government into reality, the committee made a remark that it would be possible that the TF will establish
- Policy
- Corona tx Largevrio has been urgently approved
- by Lee, Hye-Kyung Mar 24, 2022 05:54am
- The MFDS (Director Kim Kang-rip) announced on the 23rd that it has decided on the EUA of Largevrio developed by Merck and imported by MSD Korea. Largevrio can be used in patients with severe liver and kidney disorders who are difficult to use injection-type treatments, and patients who cannot take Paxlovid, a conventional PO treatment, for
- Policy
- Ahn to tap on “domestic production of Paxlovid generic”
- by Lee, Jeong-Hwan Mar 24, 2022 05:54am
- President-elect Suk-Yeol Yoon’s transition committee is pursuing the manufacture of a generic version of the oral COVID-19 treatment, Paxlovid. The government plans to ask Pfizer whether it would be possible to produce generic copies of Paxlovid in exchange for royalties. At a press conference of the transition team that was held in
- Policy
- The price of Biktarvy will be lowered next month through PVA
- by Lee, Jeong-Hwan Mar 24, 2022 05:54am
- Gilead Science Korea's HIV treatment drug Biktarvy will be reduced by signing PVA negotiations. The price will be adjusted from 24,631 won to 23,900 won and the new drug price is expected to take effect from April 1. According to the industry on the 21st, the MOHW is pushing for a "revision of the drug benefit list and upper limit table" with
- Policy
- EUA of Lagevrio imminent…interest focused on its treatment
- by Lee, Jeong-Hwan Mar 23, 2022 05:51am
- Whether the US company Merck (MSD)’s oral COVID-19 treatment Lagevrio (molnupiravir) will settle in Korea as an alternative to Paxlovid (nirmatrelvir, ritonavir) is gaining attention. The company had applied for the emergency use authorization of molnupiravir to the Ministry of Food and Drug Safety in November last year but has not been
- Policy
- Rozlytrek & Vitrakvi are likely to be listed in April
- by Lee, Tak-Sun Mar 22, 2022 05:54am
- Bayer Korea's Vitrakvi and Roche Korea's Rozlytrek completed drug price negotiations and are likely to register their benefits in April. Both drugs are used to treat solid cancer in adults and children with confirmed NTRK gene fusion. If NTRK gene fusion is confirmed, it can be administered regardless of cancer. According to the industry o
- Policy
- Actemra is likely to be reimbursed for managing CRS
- by Kim, Jung-Ju Mar 21, 2022 05:55am
- Actemra (Tocilizumab 200mg), imported by JW Pharmaceutical and used to treat rheumatoid arthritis, is also expected to be paid for CRS management. The MOHW announced on the 18th some amendments to the "Details on the Application Criteria and Methods of Nursing Benefits" containing such contents. Actemra is a drug approved for adult rheumatoid
- Policy
- In/outpt Rx for Paxlovid are available in nursing hospitals
- by Lee, Jeong-Hwan Mar 21, 2022 05:55am
- Nursing hospitals will be able to prescribe outpatient & inpatient Rx for Paxlovid, a COVID-19 treatment. Both outpatient prescriptions that prepare and supply oral drugs at pharmacies in charge and inpatient prescriptions that receive oral drugs from hospitals dedicated to infectious diseases that supply treatments have become possible. The
- Policy
- Oral myeloid leukemia treatment Onureg to be soon approved
- by Lee, Hye-Kyung Mar 18, 2022 05:56am
- The domestic marketing authorization for BMS’s acute myeloid leukemia (AML) treatment, ‘Onureg tablet (azacytidine).’ Is imminent. The safety and efficacy review for the marketing authorization of Onureg, which had received FDA approval in 2020, is now complete in Korea. According to industry sources on the 16th, the Ministry of Foo
- Policy
- EUA approval of Actemra for severe COVID-19 over 2 yrs
- by Lee, Hye-Kyung Mar 17, 2022 05:58am
- Actemra can be used in severe COVID-19 patients over the age of 2. The MFDS (Director Kim Kang-rip) announced on the 15th that it approved EUA of Actemra imported by JW Pharmaceutical for severe COVID-19 patients aged two or older to prevent a shortage of treatments in advance. The seriousness referred to herein refers to hospitalized pati
